N-Methyl-D-Aspartate Receptor-Mediated Chronic Pain: New Approaches to Fibromyalgia Syndrome Etiology and Therapy

REFERENCES

• Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38(1)19–28
   PubMed Web of Science ®Google Scholar
• Goldenberg DL. Fibromyalgia syndrome a decade later: what have we learned?. Arch Intern Med 1999; 159(8)777–785
   PubMedGoogle Scholar
• Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum 1990; 33: 160–172
   PubMed Web of Science ®Google Scholar
• Winfield JB. Pain in Fibromyalgia. Rheum Dis Clin North Am. 1999; 25(1)55–79
   PubMed Web of Science ®Google Scholar
• Arroyo JF, Cohen ML. Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol 1993; 20(11)1925–1931
   PubMedGoogle Scholar
• Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain [wind-up] in patients with fibro-myalgia syndrome. Pain 2001; 91(1–2)165–175
   PubMed Web of Science ®Google Scholar
• Boissevain MD, McCain GA. Toward an integrated understanding of fibromyalgia syndrome. II. Psychological and phenomenological aspects. Pain 1991; 45(3)239–248
   Google Scholar
• Simms RW. Fibromyalgia is not a muscle disorder. Am J Med Sci 1998; 315(6)346–350
   PubMed Web of Science ®Google Scholar
• Epstein SA, Kay G, Clauw D, Heaton R, Klein D, Krupp L, Kuck J, Leslie V, Masur D, Wagner M, Waid R, Zisook S. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics 1999; 40(1)57–63
   PubMed Web of Science ®Google Scholar
• Ford CV. Somatization and fashionable diagnoses: Illness as a way of life. Scand J Work Environ Health 1997; 23(Suppl 3)7–16
   PubMedGoogle Scholar
• Geenen R, Jacobs JW, Bijlsma JW. Evaluation and management of endocrine dysfunction in fibromyalgia. Rheum Dis Clin North Am 2002; 28(2)389–404
   PubMed Web of Science ®Google Scholar
• Crofford LJ. Neuroendocrine abnormalities in fibromyalgia and related disorders. Am J Med Sci 1998; 315(6)359–366
   PubMed Web of Science ®Google Scholar
• Dessein PH, Shipton EA, Stanwix AE, Joffe BI. Neuroendocrine deficiency-mediated development and persistence of pain in fibromyalgia: a promising paradigm?. Pain 2000; 86(3)213–215
   PubMedGoogle Scholar
• Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994; 37(11)1593–1601
   PubMed Web of Science ®Google Scholar
• Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma and urinary catecholamines in primary fibro-myalgia: a controlled study. J Rheumatol. 1994; 19(1)95–97
   Google Scholar
• Sorensen J, Graven-Nielsen T, Henriksson KG, Bengtsson M, Arendt-Nielsen L. Hyperexcitability in fibromyalgia. J Rheumatol 1998; 25(1)152–155
   PubMed Web of Science ®Google Scholar
• Bendtsen L, Norregaard J, Jensen R, Olesen J. Evidence of qualitatively altered nociception in patients with fibromyalgia. Arthritis Rheum 1997; 40(1)98–102
   PubMed Web of Science ®Google Scholar
• Gibson SJ, Littlejohn GO, Gorman MM, Helme RD, Granges G. Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain 1994; 58(2)185–193
   PubMed Web of Science ®Google Scholar
• Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002; 46(5)1333–1343
   PubMed Web of Science ®Google Scholar
• Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA, Stewart KE, Alarcon GS, Mountz JD. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995; 38(7)926–938
   Google Scholar
• Desmeules JA, Cedraschi C, Rapiti E, Baumgartner E, Finckh A, Cohen P, Dayer P, Vischer TL. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003; 48(5)1420–1429
   PubMed Web of Science ®Google Scholar
• Hassett AL, Cone JD, Patella SJ, Sigal LH. The role of catastrophizing in the pain and depression of women with fibromyalgia syndrome. Arthritis Rheum 2000; 43(11)2493–2500
   PubMed Web of Science ®Google Scholar
• McEwen BS, Wingfield JC. The concept of allostasis in biology and biomedicine. Horm Behav 2003; 43(1)2–15
   PubMed Web of Science ®Google Scholar
• Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 2003; 20(5)358–373
   Google Scholar
• Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997; 4(3)134–153
   PubMed Web of Science ®Google Scholar
• Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999; 74(4)385–398
   PubMed Web of Science ®Google Scholar
• Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288(5472)1765–1769
   PubMed Web of Science ®Google Scholar
• Kandel ER. Genes, synapses, and long-term memory. J Cell Physiol 1997; 173(2)124–125
   PubMedGoogle Scholar
• Lewin MR, Walters ET. Cyclic GMP pathway is critical for inducing long-term sensitization of nociceptive sensory neurons. Nat Neurosci 1999; 2(1)18–23
   PubMedGoogle Scholar
• Ressler KJ, Paschall G, Zhou XL, Davis M. Regulation of synaptic plasticity genes during consolidation of fear conditioning. J Neurosci 2002; 22: 7892–7902
   PubMedGoogle Scholar
• Thomas RJ. Excitatory amino acids in health and disease. J Am Geriatr Soc 1995; 43(11)1279–1289
   PubMedGoogle Scholar
• MacDermott AB, Mayer ML, Westbrook GL, Smith SJ, Barker JL. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 1986; 321(6069)519–522
   PubMedGoogle Scholar
• Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, Wang YT, Salter MW, Tymianski M. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002; 298(5594)846–850
   PubMed Web of Science ®Google Scholar
• Mayer ML, Westbrook GL, Guthrie PB. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature 1984; 309(5965)261–263
   PubMed Web of Science ®Google Scholar
• Leeson PD, Iversen LL. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J Med Chem 1994; 37(24)4053–4067
   PubMed Web of Science ®Google Scholar
• Rock DM, Macdonald RL. Polyamine regulation of N-methyl-D-aspartate receptor channels. Annu Rev Pharmacol Toxicol 1995; 35: 463–482
   PubMedGoogle Scholar
• Jansen KL, Faull RL, Dragunow M, Waldvogel H. Autoradiographic localisation of NMDA, quisqualate and kainic acid receptors in human spinal cord. Neurosci Lett 1990; 108(1–2)53–57
   PubMedGoogle Scholar
• South SM, Kohno T, Kaspar BK, Hegarty D, Vissel B, Drake CT, Ohata M, Jenab S, Sailer AW, Malkmus S, Masuyama T, Horner P, Bogulavsky J, Gage FH, Yaksh TL, Woolf CJ, Heinemann SF, Inturrisi CE. A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain. J Neurosci 2003; 23(12)5031–5040
   PubMedGoogle Scholar
• Larson AA, Giovengo SL, Russell IJ, Michalek JE. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000; 87(2)201–211
   PubMed Web of Science ®Google Scholar
• Dougherty PM, Palecek J, Paleckova V, Sorkin LS, Willis WD. The role of NMDA and non-NMDA excitatory amino acid receptors in the excitation of primate spinothalamic tract neurons by mechanical, chemical, thermal, and electrical stimuli. J Neurosci 1992; 12(8)3025–3041
   PubMed Web of Science ®Google Scholar
• Clark SR, Bennett RM. Supplemental dextromethorphan in the treatment of fibromyalgia: a double-blind, placebo-controlled study of efficacy and side-effects. Arth Rheum 2000; 43: S333
   Google Scholar
• Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, Sorensen J, Johnson A, Gerdle B, Arendt-Nielsen L. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000; 85(3)483–491
   PubMed Web of Science ®Google Scholar
• Moochhala SM, Sawynok J. Hyperalgesia produced by intrathecal substance P and related peptides: desensitization and cross desensitization. Br J Pharmacol 1984; 82: 381–388
   PubMedGoogle Scholar
• Ohtori S, Takahashi K, Ino H, Chiba T, Yamagata M, Sameda H, Moriya H. Up-regulation of substance P and NMDA receptor mRNA in dorsal horn and preganglionic sympathetic neurons during adjuvant-induced noxious stimulation in rats. Ann Anat 2002; 184(1)71–76
   PubMedGoogle Scholar
• Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated cerebrospinal fluid levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1998; 32(1)21–26
   Google Scholar
• Strittmatter M, Grauer M, Isenberg E, Hamann G, Fischer C, Hoffmann KH, Blaes F, Schimrigk K. Cerebrospinal fluid neuropeptides and monoaminergic transmitters in patients with trigeminal neuralgia. Headache 1997; 37(4)211–216
   PubMedGoogle Scholar
• Gallai V, Alberti A, Gallai B, Coppola F, Floridi A, Sarchielli P. Glutamate and nitric oxide pathway in chronic daily headache: evidence from cerebrospinal fluid. Cephalalgia 2003; 23(3)166–174
   PubMed Web of Science ®Google Scholar
• Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995; 57: 683–706
   PubMed Web of Science ®Google Scholar
• Takano Y, Kuno Y, Sato E, Takano M, Sato I. Hyperalgesia induced by intrathecal administration of nitroglycerin involves NMDA receptor activation in the spinal cord. Masui 1997; 46(10)1354–1361
   PubMedGoogle Scholar
• Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate [NMDA] receptors in pain: A review. Anesthesia & Analgesia 2003; 97(4)1108–1116
   PubMed Web of Science ®Google Scholar
• Walker EA, Keegan D, Gardner G, Sullivan M, Katon WJ, Bernstein D. Psychosocial factors in fibro-myalgia compared with rheumatoid arthritis: I. Psychiatric diagnoses and functional disability. Psychosomatic Medicine 1997; 59(6)565–571
   Google Scholar
• Malt EA, Berle JE, Olafsson S, Lund A, Ursin H. Fibromyalgia is associated with panic disorder and functional dyspepsia with mood disorders. A study of women with random sample population controls. J Psychosom Res 2000; 49(5)285–289
   Google Scholar
• Alexander RW, Bradley LA, Alarcon GS, Triana-Alexander M, Aaron LA, Alberts KR, Martin MY, Stewart KE. Sexual and physical abuse in women with fibromyalgia: association with outpatient health care utilization and pain medication usage. Arthritis Care Res 1998; 11(2)102–115
   PubMed Web of Science ®Google Scholar
• Anderberg UM, Marteinsdottir I, Theorell T, von Knorring L. The impact of life events in female patients with fibromyalgia and in female healthy controls. Eur Psychiatry 2000; 15(5)295–301
   PubMedGoogle Scholar
• Sherman JJ, Turk DC, Okifuji A. Prevalence and impact of posttraumatic stress disorder-like symptoms on patients with fibromyalgia syndrome. Clin J Pain 2000; 16: 127–134
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?. Gastroenterology 2002; 122(4)1140–1156
   PubMed Web of Science ®Google Scholar
• Johnson M, Paananen ML, Rahinantti P, Hannonen P. Depressed fibromyalgia patients are equipped with an emphatic competence dependent self-esteem. Clinical Rheumatology 1997; 16(6)578–584
   PubMedGoogle Scholar
• Gaston-Johansson F, Gustafsson M, Felldin R, Sanne H. A comparative study of feelings, attitudes and behaviors of patients with fibromyalgia and rheumatoid arthritis. Social Science & Medicine 1990; 31(8)941–947
   PubMedGoogle Scholar
• Callahan LF, Smith WJ, Pincus T. Self-report questionnaires in five rheumatic diseases: comparisons of health status constructs and associations with formal education level. Arthritis Care Res 1998; 2(4)122–131
   Google Scholar
• Ruda MA, Ling QD, Hohmann AG, Peng YB, Tachibana T. Altered nociceptive neuronal circuits after neonatal peripheral inflammation. Science 2000; 289(5479)628–631
   PubMed Web of Science ®Google Scholar
• Teicher MH, Andersen SL, Polcari A, Anderson CM, Navalta CP. Developmental neurobiology of childhood stress and trauma. Psychiatr Clin North Am 2002; 25(2)397–426, vii-viii
   PubMed Web of Science ®Google Scholar
• Kaufman J, Birmaher B, Perel J, Dahl RE, Moreci P, Nelson B, Wells W, Ryan ND. The corticotropin-releasing hormone challenge in depressed abused, depressed nonabused, and normal control children. Biol Psychiatry 1997; 42: 669–679
   PubMed Web of Science ®Google Scholar
• Levine S. Influence of psychological variable on the activity of the hypothalamic-pituitary-adrenal axis. Eur J Pharmacol 2000; 29: 149–160
   Google Scholar
• Chrousos GP. Stress, chronic inflammation, and emotional and physical well-being: concurrent effects and chronic sequelae. J Allergy Clin Immunol 2000; 106(5 Suppl)S275–291
   Google Scholar
• Takahashi T, Kimoto T, Tanabe N, Hattori TA, Yasumatsu N, Kawato S. Corticosterone acutely prolonged N-methyl-d-aspartate receptor-mediated Ca2+ elevation in cultured rat hippocampal neurons. J Neurochem 2002; 83(6)1441–1451
   PubMed Web of Science ®Google Scholar
• Weiland NG, Orchinik M, Tanapat P. Chronic corticosterone treatment induces parallel changes in N-methyl-D-aspartate receptor subunit messenger RNA levels and antagonist binding sites in the hippocampus. Neuroscience 1997; 78: 653–662
   PubMed Web of Science ®Google Scholar
• Drummond PD. The effect of noradrenaline, angiotensin II and vasopressin on blood flow and sensitivity to heat in capsaicin-treated skin. Clin Auton Res 1998; 8(2)87–93
   PubMedGoogle Scholar
• Calis M, Gokce C, Ates F, Ulker S, Izgi HB, Demir H, Kirnap M, Sofuoglu S, Durak AC, Tutus A, Kelestimur F. Investigation of the hypothalamo-pituitary-adrenal axis [HPA] by 1 microg ACTH test and metyrapone test in patients with primary fibromyalgia syndrome. J Endocrinol Invest 2004; 27(1)42–46
   PubMed Web of Science ®Google Scholar
• Magiakou MA, Chrousos GP. Corticosteroid therapy, nonendocrine disease, and corticosteroids withdrawal. Curr Ther Endocrinol Metab 1994; 5: 120–124
   PubMedGoogle Scholar
• LeDoux J. The emotional brain, fear, and the amygdala. Cell Mol Neurobiol 2003; 23(4–5)727–738
   PubMed Web of Science ®Google Scholar
• McEwen BS. The neurobiology and neuroendo-crinology of stress. Implications for post-traumatic stress disorder from a basic science perspective. Psychiatr Clin North Am 2002; 25(2)469–494
   Google Scholar
• Yang B, Wang Y, Cynader MS. Synergistic interactions between noradrenaline and glutamate in cytosolic calcium influx in cultured visual cortical neurons. Brain Res 1996; 721(1–2)181–190
   PubMedGoogle Scholar
• Raj S, Brouillard D, Simpson CS, Hopman WM, Abdollah H. Dysautonomia among patients with fibro-myalgia: a noninvasive assessment. J Rheumatol 2000; 27: 2660–2665
   PubMed Web of Science ®Google Scholar
• Cohen H, Neumann L, Haiman Y, Matar MA, Press J, Buskila D. Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndromes or post-traumatic fibromyalgia syndrome. Semin Arthritis Rheum 2002; 32: 38–50
   PubMed Web of Science ®Google Scholar
• Dentino AN, Pieper CF, Rao MK, Currie MS, Harris T, Blazer DG, Cohen HJ. Association of inter-leukin-6 and other biologic variables with depression in older people living in the community. J Am Geriatr Soc 1999; 47(1)6–11
   PubMed Web of Science ®Google Scholar
• Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52(4)595–638
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 2001; 40(7)743–749
   PubMed Web of Science ®Google Scholar
• Papanicolaou DA, Vgontzas AN. Interleukin-6: the endocrine cytokine. J Clin Endocrinol Metab 2001; 85(3)1331–1333
   Google Scholar
• Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993; 77: 1690–1694
   PubMed Web of Science ®Google Scholar
• De Jongh RF, Vissers KC, Meert TF, Booij LH, De Deyne CS, Heylen RJ. The role of interleukin-6 in nociception and pain. Anesth Analg 2003; 96(4)1096–1103
   PubMed Web of Science ®Google Scholar
• Ploj K, Roman E, Bergstrom L, Nylander I. Effects of neonatal handling on nociceptin/orphanin FQ and opioid peptide levels in female rats. Pharmacol Biochem Behav 2001; 69(1–2)173–179
   PubMedGoogle Scholar
• Millan MJ, Morris BJ, Colpaert FC, Herz A. A model of chronic pain in the rat: high-resolution neuro-anatomical approach identifies alterations in multiple opioid systems in the periaqueductal grey. Brain Res 1997; 416(2)349–353
   Google Scholar
• Mao J, Mayer DJ. Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain. Ann N Y Acad Sci 2001; 933: 175–184
   PubMed Web of Science ®Google Scholar
• Trujillo KA. The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity. Neurotox Res 2002; 4(4)373–391
   PubMed Web of Science ®Google Scholar
• Li X, Clark JD. Hyperalgesia during opioid abstinence: mediation by glutamate and substance P. Anesth Analg 2002; 95(4)979–984
   PubMedGoogle Scholar
• Panerai AE, Vecchiet J, Panzeri P, Meroni P, Scarone S, Pizzigallo E, Giamberardino MA, Sacerdote P. Peripheral blood mononuclear cell beta-endorphin concentration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report. Clin J Pain 2002; 18(4)270–273
   PubMedGoogle Scholar
• Welin M, Bragee B, Nyberg F, Kristiansson M. Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in cerebrospinal program from fibromyalgia patients. J Musculoske Pain 1995; 3(Suppl 1)4
   Google Scholar
• Millea PJ, Holloway RL. Treating fibromyalgia. Am Fam Physician 2000; 62(7)1575–1587
   PubMedGoogle Scholar
• Rao SG, Clauw DJ. The management of fibro-myalgia. Drugs Today 2004; 40(6)539–554
   PubMed Web of Science ®Google Scholar
• Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004; 292(19)2388–2395
   PubMed Web of Science ®Google Scholar
• Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, Edworthy SM, Baron M, Koehler BE, Fam AG, Bellamy N, Guimont C. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double blind clinical trial. Arthritis Rheum; 1994; 37(1)32–40
   PubMed Web of Science ®Google Scholar
• Lawson K. Tricyclic antidepressants and fibro-myalgia: what is the mechanism of action?. Expert Opin Investig Drugs 2002; 11(10)1437–1445
   PubMed Web of Science ®Google Scholar
• McCain GA, Bell DA, Mai FM, Halliday PD. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum 1988; 31(9)1135–1141
   PubMed Web of Science ®Google Scholar
• Burckhardt CS. Nonpharmacologic management strategies in fibromyalgia. Rheum Dis Clin North Am 2002; 28(2)291–304
   PubMedGoogle Scholar
• Greenberg PE, Leong SA, Birnbaum HG, Robinson RL. The economic burden of depression with painful symptoms. J Clin Psychiatry 2003; 64(Suppl 7)17–23
   PubMedGoogle Scholar
• Henriksson KG, Sorensen J. The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia. Rheum Dis Clin North Am 2002; 28(2)343–351
   PubMedGoogle Scholar
• Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Pain, Palliative Care and Supportive Care Group Cochrane Database of Systematic Reviews 2004; 4
   Google Scholar
• Kristensen JD, Svensson B, Gordh T, Jr. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain 1992; 51(2)249–253
   PubMed Web of Science ®Google Scholar
• Nikolajsen L, Hansen CL, Nielsen J, Keller J, Arendt-Nielsen L, Jensen TS. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain 1996; 67(1)69–77
   PubMedGoogle Scholar
• Weinbroum AA, Gorodetzky A, Nirkin A, Kollender Y, Bickels J, Marouani N, Rudick V, Meller I. Dextromethorphan for the reduction of immediate and late postoperative pain and morphine consumption in orthopedic oncology patients: a randomized, placebo-controlled, double-blind study. Cancer 2002; 95(5)1164–1170
   PubMed Web of Science ®Google Scholar
• Hoffmann V, Coppejans H, Vercauteren M, Adriaensen H. Successful treatment of postherpetic neuralgia with oral ketamine. Clin J Pain 1994; 10(3)240–242
   PubMedGoogle Scholar
• Broadley KE, Kurowska A, Tookman A. Ketamine injection used orally. Palliat Med 1996; 10(3)247–250
   PubMed Web of Science ®Google Scholar
• Church J, Lodge D, Berry SC. Differential effects of dextromethorphan and levorphanol on the excitation of rat spinal neurons by amino acids. Eur J Pharmacol 1985; 111(2)185–190
   PubMed Web of Science ®Google Scholar
• Weinbroum AA, Gorodezky A, Niv D, Ben-Abraham R, Rudick V, Szold A. Dextromethorphan attenuation of postoperative pain and primary and secondary thermal hyperalgesia. Can J Anaesth 2001; 48(2)167–174
   PubMedGoogle Scholar
• Weinbroum AA, Rudick V, Paret G, Ben-Abraham R. the role of dextromethorphan in pain control. Can J Anaesth. 2000; 47(6)585–596
   PubMedGoogle Scholar
• Freye E, Levy J. Acute abstinence syndrome following abrupt cessation of long-term use of tramadol [Ultram]: A case study. Eur J Pain 2000; 4(3)307–311
   PubMed Web of Science ®Google Scholar
• Bennett GJ. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J Pain Symptom Manage 2000; 19(Suppl 1)S2–6
   Google Scholar
• Baker AK, Hoffmann VL, Meert TF. Interactions of NMDA antagonists and an alpha 2 agonist with mu, delta and kappa opioids in an acute nociception assay. Acta Anaesthesiol Belg 2002; 53(3)203–212
   PubMedGoogle Scholar
• Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes? Drugs 1998; 55(1)1–4
   Google Scholar
• Tao F, Tao YX, Mao P, Johns RA. Role of postsynaptic density protein-95 in the maintenance of peripheral nerve injury-induced neuropathic pain in rats. Neuroscience 2003; 117(3)731–739
   PubMedGoogle Scholar
• Claiborne CF, McCauley JA, Libby BE, Curtis NR, Diggle HJ, Kulagowski JJ, Michelson SR, Anderson KD, Claremon DA, Freidinger RM, Bednar RA, Mosser SD, Gaul SL, Connolly TM, Condra CL, Bednar B, Stump GL, Lynch JJ, Macaulay A, Wafford KA, Koblan KS, Liverton NJ. Orally Efficacious NR2B-Se-lective NMDA Receptor Antagonists. Bioorg Med Chem Lett 2003; 13(4)697–700
   PubMedGoogle Scholar
• Tao YX, Huang YZ, Mei L, Johns RA. Expression of PSD-95/SAP90 is critical for N-methyl-D-aspartate receptor-mediated thermal hyperalgesia in the spinal cord. Neuroscience 2000; 98(2)201–206
   PubMedGoogle Scholar
• Tao YX, Johns RA. Effect of the deficiency of spinal PSD-95/SAP90 on the minimum alveolar anesthetic concentration of isoflurane in rats. Anesthesiology 2001; 94(6)1010–1015
   PubMedGoogle Scholar
• Garry EM, Moss A, Delaney A, O'Neill F, Blakemore J, Bowen J, Husi H, Mitchell R, Grant SG, Fleetwood-Walker SM. Neuropathic sensitization of behavioral reflexes and spinal NMDA receptor/CaM kinase II interactions are disrupted in PSD-95 mutant mice. Curr Biol 2003; 13(4)321–328
   PubMed Web of Science ®Google Scholar
• Tao F, Tao YX, Gonzalez JA, Fang M, Mao P, Johns RA. Knockdown of PSD-95/SAP90 delays the development of neuropathic pain in rats. Neuroreport 2001; 12(15)3251–3255
   PubMedGoogle Scholar
• Chizh BA, Reissmuller E, Schlutz H, Scheede M, Haase G, Englberger W. Supraspinal versus spinal sites of the antinociceptive action of the subtype-selective NMDA antagonist ifenprodil. Neuropharmacology 2001; 40(2)212–220
   PubMedGoogle Scholar
• Tan-No K, Esashi A, Nakagawasai O, Niijima F, Sakurada C, Sakurada T, Bakalkin G, Terenius Tadano T. Nociceptive behavior induced by poly-L-lysine and other basic compounds involves the spinal NMDA receptors. Brain Res 2004; 1008(1)49–53
   PubMedGoogle Scholar
• Zhang GH, Min SS, Lee KS, Back SK, Yoon SJ, Yoon YW, Kim YI, Na HS, Hong SK, Han HC. Intra-articular pretreatment with ketamine and memantine could prevent arthritic pain: relevance to the decrease of spinal c-fos expression in rats. Anesthesia & Analgesia 2004; 99(1)152–158
   PubMedGoogle Scholar
• Medvedev IO, Malyshkin AA, Belozertseva IV, Sukhotina IA, Sevostianova NY, Aliev K, Zvartau EE, Parsons CG, Danysz W, Bespalov AY. Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology 2004; 47(2)175–183
   PubMedGoogle Scholar
• Suzuki R, Matthews EA, Dickenson AH. Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy. Pain 2001; 91(1–2)101–109
   PubMed Web of Science ®Google Scholar
• Sang CN, Booher S, Gilron I, Parada S, Max MB. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002; 96(5)1053–1061
   PubMed Web of Science ®Google Scholar
• Marchettini P, Teloni L, Formaglio F, Lacerenza M. Pain in diabetic neuropathy case study: whole patient management. Euro J Neuro 2004; 11(Suppl 1)12–21
   Google Scholar
• Wiech K, Kiefer RT, Topfner S, Preissl H, Braun C, Unertl K, Flor H, Birbaumer N. A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesthesia & Analgesia 2004; 98(2)408–413
   PubMed Web of Science ®Google Scholar
• Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Familial aggregation of depression in fibromyalgia: a community-based test of alternate hypotheses. Pain 2004; 110(1–2)449–460
   PubMedGoogle Scholar
• Offenbaecher M, Bondy B, De Jonge S, Glat-zeder K, Kruger M, Schoeps P, Ackenheil M. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999; 42(11)2482–2488
   PubMedGoogle Scholar
• Bondy B, Spaeth M, Offenbaecher M, Glatzeder K, Stratz T, Schwarz M, De Jonge S, Kruger M, Engel RR, Farber L, Pongratz DE, Ackenheil M. The T102C polymorphism of the 5-HT2A-receptor gene in fibro-myalgia. Neurobiol Dis 1999; 6(5)433–439
   PubMedGoogle Scholar
• Cull-candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001; 11(3)327–335
   PubMed Web of Science ®Google Scholar